Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin's Next Stop May Be Hearing As FDA Starts Withdrawal Process For Breast Cancer Claim

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency officials stress that FDA is eager to work with Genentech on future studies to identify a subpopulation of responders.

You may also be interested in...



House Approps Bill Would "Harden" Science Requirements For FDA Rules, Guidance

Provision meant to protect ranchers/farmers could unleash Pandora's box of impediments to regulations, guidance; panel debates Avastin.

House Approps Bill Would "Harden" Science Requirements For FDA Rules, Guidance

Provision meant to protect ranchers/farmers could unleash Pandora's box of impediments to regulations, guidance; panel debates Avastin.

Roche Succeeds In Changing EMA Ruling On Avastin

The Committee for Medicinal Products for Human Use has reversed its previous rejection and is granting an indication for treatment of first-line breast cancer in combination with capecitabine.

Related Content

Topics

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel